(Q39361381)

11 September 2017

title

Efficacy of oral naratriptan in the treatment of menstrually related migraine (English)

1 reference

11 September 2017

1 reference

1 reference

H Massiou

1

1 reference

11 September 2017

C Jamin

2

1 reference

11 September 2017

G Hinzelin

3

1 reference

11 September 2017

C Bidaut-Mazel

4

1 reference

11 September 2017

French Naramig Collaborative Study Group

5

1 reference

11 September 2017

publication date

1 October 2005

1 reference

European Journal of Neurology

11 September 2017

published in

1 reference

11 September 2017

volume

12

1 reference

11 September 2017

issue

10

1 reference

11 September 2017

page(s)

774-781

1 reference

Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Menstrual Migraine in A Representative Dutch Population Sample: Prevalence, Disability and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Determinants of patient satisfaction with migraine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Assessing the impact of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Migraine and reporoductive hormones throughout the menstrual cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Off-label prescribing of drugs in specialty headache practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Prevalence of migraine on each day of the natural menstrual cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Rizatriptan in the treatment of menstrual migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01076.X

10.1111/J.1468-1331.2005.01076.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference